A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Hoffmann-La Roche
With
Zealand Pharma
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with BMI ≥ 27 kg/m² and established CVD
History of at least one self-reported unsuccessful dietary effort to lose body weight
You may not be if
Known history of Type 1 diabetes mellitus
Current or previous treatment with petrelintide or any other amylin analog
Clareo Health | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
